Catalina Capital Group’s AbbVie ABBV Stock Holding History

Catalina Capital Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$546K	Buy	2,511 +35	+1%	+$7.76K	0.33%	68
2025 Q4	$566K	Sell	2,476 -19	-0.8%	-$4.33K	0.34%	64
2025 Q3	$578K	Buy	2,495 +13	+0.5%	+$2.65K	0.35%	61
2025 Q2	$461K	Sell	2,482 -767	-24%	-$143K	0.3%	69
2025 Q1	$681K	Sell	3,249 -7,421	-70%	-$1.44M	0.45%	52
2024 Q4	$1.9M	Buy	10,670 +557	+6%	+$102K	0.62%	33
2024 Q3	$2M	Buy	10,113 +903	+10%	+$169K	0.67%	32
2024 Q2	$1.58M	Buy	9,210 +2,292	+33%	+$380K	0.59%	35
2024 Q1	$1.26M	Buy	6,918 +3,628	+110%	+$625K	0.52%	41
2023 Q4	$510K	Buy	+3,290	New	+$480K	0.34%	57

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Catalina Capital Group's ABBV Position: Q1 2026 in Review

Catalina Capital Group increased its AbbVie (ABBV) stake by 1.4% in Q1 2026, buying an estimated $7.76K and bringing the position to 2,511 shares worth $546K. The position accounts for 0.33% of the portfolio, ranked #68.

Catalina Capital Group first reported a position in ABBV in Q4 2023 and has held it in 10 quarters since. The position peaked at $2M in Q3 2024. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Catalina Capital Group held 2,511 shares of AbbVie worth $546K as of Q1 2026.
Catalina Capital Group bought 35 AbbVie shares in Q1 2026, an estimated $7.76K.
AbbVie made up 0.33% of Catalina Capital Group's portfolio in Q1 2026, its #68 holding.
Catalina Capital Group first reported a position in AbbVie in Q4 2023 and has held it in 10 quarters since.
Catalina Capital Group's AbbVie position peaked at $2M in Q3 2024.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Catalina Capital Group's 13F filing for Q1 2026, filed 23 Apr 2026.